Table 3

Enhancement of the efficacy of BCNU with dBG against human glial tumor xenografts in athymic mice

TumorBCNUa mg/m2dBG mg/m2No. of animalNo. of deathsWeight loss Mean %No. of regressionsMedian to 5× treatment volumeT-Cb Days
D-5435300127293179
352501201292416
302501201062113
SWB61352501201082614
35200120772513
SWB3935250120972211
SWB403525013010114029
SWB77352501209124938
SWB773525014012144130
  • a BCNU stock 10 mg/ml in 100% ethanol was diluted to appropriate concentrations with 5% ethanol. dBG was dissolved in 40% PEG in PBS. BCNU was injected i.p. (injection volume, 0.15–0.2 ml/animal) 2 h after treatment with i.p. dBG (injection volume, 0.2–0.3 ml/animal).

  • b T-C tumor growth delay. All values were statistically significant as compared with untreated controls.